Non-regulatory
announcement
ONDINE BIOMEDICAL
INC.
("Ondine
Biomedical", "Ondine", or the "Company")
32% Fewer SSIs After
Steriwave Replaced Mupirocin
New data shows reduced
cardiac infections and significant cost savings after the
light-activated antimicrobial, Steriwave, replaced the antibiotic
standard of care at the Mazankowski Alberta Heart
Institute
Ondine Biomedical Inc. (LON: OBI), the Canadian life
sciences company pioneering light-activated antimicrobial
treatments, announces that an independent study undertaken at the
world renowned Mazankowski Alberta Heart Institute demonstrated a
32% reduction in cardiac surgical site infections (SSIs) following
the implementation of Steriwave as a replacement for the antibiotic
Mupirocin. Researchers from the University of Alberta presented
this data in a poster at the AMMI Canada-CACMID annual
conference, a major conference on clinical microbiology and
infectious diseases.
In June 2023, Steriwave was implemented on a pilot
basis as a replacement for the antibiotic Mupirocin, which has
resistance rates as high as 81% and is used by many hospitals as
the standard of care for the prevention of SSIs.[1] The
average SSI rate prior to the implementation of Steriwave was 1.67
per 100 surgeries, and the final rate following the implementation
of Steriwave was 0.7 per 100 surgeries. The researchers estimated
that this reduction in SSIs represented a $56,000 cost saving
during the quarter. The compliance rate for Steriwave was 94%, and
treatment was well-tolerated with no adverse reactions
reported.
Lead author Dr. Stephanie Smith, Director of Hospital
Infection Prevention and Control at the University of Alberta
Hospital and the Mazankowski Alberta Heart Institute, commented:
"We are very pleased to be able to share these initial results from
the Steriwave pilot. To see a reduction in SSIs in excess of
the already low rate we had when using Mupirocin is fantastic,
particularly as many hospitals are looking to reduce their use of
Mupirocin because of challenges with compliance and concerns about
antibiotic resistance."
SSIs are one of the most significant
complications in cardiac surgery patients and are strongly
associated with poorer prognosis. SSIs can complicate up to 27% of
cardiac surgery procedures[2] and result in
substantially higher costs because of the need for additional
treatments and extended patient recovery time. Nasal decolonization
has been found to significantly decrease SSIs caused by the
infection-causing pathogen S.
aureus following cardiac procedures.[3]
Steriwave is a broad-spectrum light-activated
antimicrobial that uses a patented photosensitizer and associated
red activating light to destroy pathogens in the nose. The nose is
a major reservoir of bacteria, fungi and viruses which can spread
and cause serious infections. Unlike traditional antibiotics,
Steriwave is immediately effective with a single five-minute
treatment and does not trigger antimicrobial resistance (AMR).
Mupirocin, as well as having high resistance rates,
tends to have a low compliance rate less than 40%, as patients need
to self-administer in the five days leading up to their surgery.
Both these factors led to
Alberta Health Services' previously announced decision to expand
its use of Steriwave.
About the pilot:
The Mazankowski Alberta Heart Institute pilot
commenced in June 2023. Between June 2023 and February 2024,
Steriwave was used to nasally decolonize 828 patients prior to
cardiac surgery. The Steriwave compliance rate was 94%, and it was
well-tolerated with no adverse reactions reported. The results
presented at the AMMI Canada-CACMID annual conference were based on
data including the first three months of the pilot.
**ENDS**
Enquiries:
Ondine Biomedical
Inc.
|
|
Carolyn Cross, CEO
|
+001 (604) 665 0555
|
|
|
Singer Capital Markets (Nominated Adviser and Joint
Broker)
|
|
Aubrey Powell, Sam
Butcher
|
+44 (0)20 7496 3000
|
|
|
RBC
Capital Markets (Joint Broker)
|
|
Rupert Walford, Kathryn
Deegan
|
+44 (0)20 7653 4000
|
|
|
Vane Percy & Roberts (Media Contact)
|
|
Simon Vane Percy, Amanda
Bernard
|
+44 (0)77 1000 5910
|
About The
Mazankowski Alberta Heart Institute
The Mazankowski Alberta Heart Institute in Edmonton
is a world leader in complex cardiac care and surgery. With a
collaborative approach, our team of highly skilled cardiologists,
cardiovascular surgeons, cardiac care professionals, researchers
and educators are advancing the prevention, detection, treatment
and study of cardiovascular disease.
About Ondine
Biomedical Inc.
Ondine Biomedical Inc. is a Canadian life science
company and a world leader in the development and clinical use of
light-activated antimicrobial therapies (also known as
'photodisinfection'). Based on its proprietary light-activated
technology, Ondine has a pipeline of investigational products in
various stages of development.
Ondine's nasal decolonisation light-activated
technology has a CE mark in Europe and the UK-CA mark, and is
approved in Canada and several other countries under the name
Steriwave®. In the US, it has been granted Qualified Infectious
Disease Product designation and Fast Track status by the FDA and is
currently undergoing clinical trials for regulatory approval.
Light-activated antimicrobial products in development include
therapies for a variety of medical indications such as chronic
sinusitis, ventilator-associated pneumonia, burns, and other
indications.
About
Steriwave®
Ondine's Steriwave is a patented technology using a
proprietary light-activated antimicrobial (photosensitizer) to
destroy bacteria, viruses, and fungi colonizing the nose - a major
reservoir of pathogens. The treatment is carried out by a trained
healthcare professional and is an easy-to-use, painless, two-step
process. The photosensitizer is applied to each nostril using
a nasal swab, followed by illumination of the area with a specific
wavelength of red light for less than five minutes. The light
activates the photosensitizer, causing an oxidative burst that is
lethal to all types of pathogens without causing long-term adverse
effects on the nasal microbiome. A key benefit of this approach,
unlike with antibiotics which have resistance rates reported as
high as 81%,1 is that pathogens do not develop
resistance to the therapy.
Nasal decolonization is recommended in the 2016 WHO
Global guidelines for the prevention of surgical site
infections,[4] and the Society for
Healthcare Epidemiology of America (SHEA) guidelines, published in
May 2023, recommend nasal decolonisation for major surgical
procedures.[5]